The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
Open accessAbstract
Purpose: Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. Patients and Methods: In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20). Results: For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. Conclusion: These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
Self-citationLongitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W. C. T., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., & Isaacs, W. B. (1999) · PubMed · Cited by 1,051
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Self-citation
Cited by
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3
Salameh, A., Lee, A. K., Cardó-Vila, M., Nunes, D. N., Efstathiou, E., Staquicini, F. I., Dobroff, A. S., Marchiò, S., Navone, N. M., Hosoya, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507882112 · Cited by 277
Emerging proteomics biomarkers and prostate cancer burden in Africa
Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16568 · Cited by 26
Metadata
- Authors
- Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., Bidair, M., Lin, D. W., Taneja, S. S., Viterbo, R., Joon, A. Y., Dahlgren, J., Kagan, J., Srivastava, S., & Sanda, M. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-12-20
- Volume
- 32
- Issue
- 36
- Pages
- 4066-4072
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1970408952
- Cited by
- 274
- References
- 34
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer? https://app.cochat.ai/papers/10.1200/jco.2013.52.8505
- The paper
- Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., Bidair, M., Lin, D. W., Taneja, S. S., Viterbo, R., Joon, A. Y., Dahlgren, J., Kagan, J., Srivastava, S., & Sanda, M. G. (2014). Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer? Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.52.8505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
